Related Experiment Video
Updated: Sep 25, 2026
Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
Published on: September 15, 2017
Circulating angiogenic and inflammatory biomarkers profiling in patients with hereditary hemorrhagic telangiectasia
Bernat Villanueva1, Agnès Figueras2, Raquel Torres-Iglesias1
1Hereditary Hemorrhagic Telangiectasia Unit, Hospital Universitari de Bellvitge, Barcelona, Spain; Department of Internal Medicine, Hospital Universitari de Bellvitge, Barcelona, Spain; Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain; Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.
Background:
Hereditary hemorrhagic telangiectasia (HHT) is an inherited vascular disorder affecting BMP9-ALK1-endoglin signaling, leading to vascular malformations. HHT is marked by recurrent bleeding (mostly epistaxis and gastrointestinal) that can result in severe anemia. Thus, there is a need for circulating biomarkers to quantify clinical severity, monitor response to anti-angiogenic therapies such as bevacizumab and to support diagnosis.
Materials And Methods:
This is an exploratory, observational, prospective study conducted in an HHT referral Unit. We profiled 22 circulating angiogenic and inflammatory biomarkers in nine bevacizumab-treated HHT patients, 1:1 matched with HHT controls and healthy controls. HHT patients with indication for bevacizumab treatment underwent blood sampling before and during treatment. The main objective is to describe the evolution of these biomarkers during bevacizumab treatment. Secondary objectives were to identify (i) biomarkers associated with HHT diagnosis, and (ii) biomarkers that scale with anemia severity using hemoglobin (Hb).
Results:
Circulating VEGF-A increased markedly during bevacizumab treatment, precluding its use as a monitoring biomarker. PDGF, TSP1, sVEGFR1, FGF2, VEGFc, and PLGF significantly change from baseline in responders, with PDGF and TSP1 showing significantly higher end-of-treatment levels compared to non-responders. Comparing HHT patients to non-HHT controls at baseline, BMP9, sENG, sVEGFR1, sVEGFR2, VEGFc, TSP1, TSP2, and PDGF levels were significantly downregulated, whereas IL-6 was increased. Finally, VEGFc, sVEGFR1, and TSP1 positively correlated with Hb levels.
Conclusions:
These data identify candidate circulating biomarkers for monitoring bevacizumab response and quantifying HHT disease burden. Further studies are needed to validate these findings.
